Hughes' syndrome: the antiphospholipid syndrome. A historical view.
In the 15 years since our description of the antiphospholipid syndrome, it has become recognised as an important disease, not only in the world of lupus but in the broader areas of obstetrics, neurology and vascular disease. Although advances have been made in the understanding of the interactions of antibodies, protein co-factors, clotting molecules, endothelium and platelets, much still needs to be learnt about management where strokes, in particular, continue to cause significant morbidity.
Hughes
G R
GR
Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, UK.
D000026:Abortion, Habitual / Q000276:immunology; D017152:Antibodies, Antiphospholipid / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000209:etiology / Q000266:history* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000209:etiology / Q000266:history* / Q000276:immunology; D003226:Congresses as Topic; D004739:England; D005260:Female; D006023:Glycoproteins / Q000266:history / Q000276:immunology; D049673:History, 20th Century; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D011247:Pregnancy; D012859:Sjogren's Syndrome / Q000150:complications; D019851:Thrombophilia / Q000276:immunology; D053482:beta 2-Glycoprotein I
D017152:Antibodies, Antiphospholipid; D001324:Autoantigens; D006023:Glycoproteins; D016682:Lupus Coagulation Inhibitor; D053482:beta 2-Glycoprotein I